文献速递免疫规划卫生政策与健康促进

中国儿童不同流感疫苗接种策略的成本效果与健康影响

Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China.
PubMed 文献 · Am J Prev Med · 2023-04-08

研究构建两个决策分析模型,模拟中国6月龄至18岁儿童四种流感疫苗接种策略,从社会角度评估2021年成本、质量调整生命年损失及可避免的病例和死亡。3至18岁儿童中,四价灭活疫苗相比三价灭活疫苗具有成本效果,增量成本效果比为32948.5美元/质量调整生命年。

要点

  • 3至18岁儿童中,四价灭活疫苗相比三价灭活疫苗具有成本效果,增量成本效果比为32948.5美元/质量调整生命年。
  • 四价灭活疫苗、三价灭活疫苗、减毒活疫苗和不接种在10000次蒙特卡洛模拟中具有成本效果的比例分别为55.94%、33.09%、10.97%和0%。

核心结论

  • 对于6月龄至18岁儿童,三价灭活疫苗相比不接种具有成本效果。
  • 在3至18岁儿童的三种疫苗接种策略中,四价灭活疫苗似乎最具成本效果。

研究设计与样本

  • 研究开发了两个决策分析模型,模拟四种疫苗接种策略。
  • 研究对象为中国6月龄至18岁儿童,评估的三款疫苗包括三价灭活疫苗、四价灭活疫苗和减毒活疫苗。
  • 结局指标包括2021年社会角度的总成本、质量调整生命年损失、可避免的门诊和住院病例数及死亡数。
  • 进行了确定性和概率敏感性分析以检验模型输入的不确定性。

主要发现

  • 对于3至18岁儿童,四价灭活疫苗相比三价灭活疫苗具有成本效果,增量成本效果比为32948.5美元/质量调整生命年(支付意愿阈值为37653美元/质量调整生命年),该结果对四价灭活疫苗相比三价灭活疫苗疫苗有效性的相对危险度敏感。
  • 若减毒活疫苗的疫苗有效性大于0.79,则其具有成本效果。
  • 概率敏感性分析显示,在10000次蒙特卡洛模拟中,四价灭活疫苗、三价灭活疫苗、减毒活疫苗和不接种具有成本效果的比例分别为55.94%、33.09%、10.97%和0%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Authors aimed to evaluate the economic and health impacts of three influenza vaccines available in China, including trivalent inactivated vaccine, quadrivalent inactivated vaccine, and live attenuated influenza vaccine, for children aged six months to 18 years. METHODS: Two decision-analytic models were developed to simulate four vaccination strategies. Outcomes included total costs from a societal perspective in 2021, quality-adjusted life-year loss, numbers of outpatient and inpatient cases, and deaths avoided using each strategy. Deterministic and probabilistic sensitivity analyses were performed to examine the uncertainty of model inputs. RESULTS: For children aged six months to three years, trivalent inactivated vaccine saved $48 million and avoided a loss of 17,637 quality-adjusted life-years compared with no vaccination. For children aged 3-18 years, quadrivalent inactivated vaccine was cost-effective compared with trivalent inactivated vaccine, with an incremental cost-effectiveness ratio of $32,948.5/quality-adjusted life-year (willingness-to-pay threshold=$37,653/quality-adjusted life-year), which was sensitive to the RR of vaccine effectiveness of quadrivalent inactivated vaccine versus of trivalent inactivated vaccine. When compared with quadrivalent inactivated vaccine, live attenuated influenza vaccine was $1.28 billion more costly but gained an additional 13,560 quality-adjusted life-years; its incremental cost-effectiveness ratio was $123,983.8/quality-adjusted life-year. Live attenuated influenza vaccine would be cost-effective if its vaccine effectiveness was >0.79. Probabilistic sensitivity analysis revealed that quadrivalent inactivated vaccine, trivalent inactivated vaccine, live attenuated influenza vaccine, and no vaccination were cost-effective in 55.94%, 33.09%, 10.97%, and 0% of 10,000 Monte Carlo simulations. CONCLUSIONS: Trivalent inactivated vaccine was cost-effective compared with no vaccination in children aged six months to 18 years. Of the three vaccination strategies for children aged 3-18 months, quadrivalent inactivated vaccine appears to be the most cost-effective.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Gong Y, Yao X, Peng J, et al. Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China. Am J Prev Med. 2023. PMID: 37037733. doi:10.1016/j.amepre.2023.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。